Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 21, 2011. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,200,000 Ordinary shares of 25 pence each.
- Purchase Date: November 21, 2011.
- Price Range: Highest price paid was 1,367.5 pence per share; lowest price paid was 1,351 pence per share.
- Treasury Holdings (Settled): 520,662,927 shares (9.34% of total issued share capital).
- Treasury Holdings (Including Unsettled): 523,662,927 shares (10.36% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,052,377,582 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,200,000 shares. Consequently, the percentage of shares held in Treasury increased to 9.34% of issued capital and 10.36% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (520,662,927 settled) against the company's latest capitalization table.
- Confirm the denominator for voting rights calculations is 5,052,377,582 shares (excluding treasury shares).
- Check the average price paid (between 1,351 and 1,367.5 pence) against the market price on November 21, 2011.
- Review the remaining authorization for share buybacks under the May 5, 2011 shareholder mandate.